Poseida Therapeutics, Inc. announced the appointment of five new members to its Gene Therapy Scientific Advisory Board (SAB). These world-class researchers will join George M. Church, Ph.D., Chair of Poseida's recently formed Gene Therapy SAB, to provide counsel on the Company's gene therapy programs in development. The new Gene Therapy SAB members are: Ian Alexander, MBBS, Ph.D., Professor of Pediatrics and Molecular Medicine at the University of Sydney, Australia; Julian Grünewald, M.D., Assistant Professor at the Technical University of Munich, Germany; Mark Kay, M.D., Ph.D., Professor of Pediatrics and Genetics at Stanford University; Mark Tracy, Ph.D., President of Tracy BioConsulting, LLC; and Kathryn Whitehead, Ph.D., Professor of Chemical Engineering and Biomedical Engineering at Carnegie Mellon University.